Source: Benzinga

Praxis: Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies

BOSTON, April 08, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be hosting a virtual investor event on Friday, May 2, 2025 from 10:00 a.m. to 11:30 a.m. EDT.The webinar, hosted by the Praxis management team, will focus on the company's clinical programs in developmental and epileptic encephalopathies (DEEs) including:The EMBOLD study ...Full story available on Benzinga.com

Read full article »
Annual Revenue
$5.0-25M
Employees
25-100
Marcio Souza's photo - President & CEO of Praxis

President & CEO

Marcio Souza

CEO Approval Rating

46/100

Read more